JP2007514662A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007514662A5 JP2007514662A5 JP2006541552A JP2006541552A JP2007514662A5 JP 2007514662 A5 JP2007514662 A5 JP 2007514662A5 JP 2006541552 A JP2006541552 A JP 2006541552A JP 2006541552 A JP2006541552 A JP 2006541552A JP 2007514662 A5 JP2007514662 A5 JP 2007514662A5
- Authority
- JP
- Japan
- Prior art keywords
- ylene
- phen
- alkyl
- nhc
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 50
- 150000001875 compounds Chemical class 0.000 claims 50
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 28
- 125000005843 halogen group Chemical group 0.000 claims 15
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 14
- 125000002947 alkylene group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 8
- 125000006239 protecting group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000000732 arylene group Chemical group 0.000 claims 7
- 125000005549 heteroarylene group Chemical group 0.000 claims 7
- 125000004450 alkenylene group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- -1 hydroxy, phenyl Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004419 alkynylene group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 3
- 102000017910 Adrenergic receptor Human genes 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 3
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000003638 chemical reducing agent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 230000001270 agonistic effect Effects 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims 2
- 230000007883 bronchodilation Effects 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003700 epoxy group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000001301 oxygen Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- QMOVGVNKXUTCQU-UHFFFAOYSA-N (2-phenylphenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 QMOVGVNKXUTCQU-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 229940015043 glyoxal Drugs 0.000 claims 1
- 150000002440 hydroxy compounds Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 C*(C)C(*)(*1)C1(C)C1(C)CC(C)(*)N(*)C*(C)C*(C)C1 Chemical compound C*(C)C(*)(*1)C1(C)C1(C)CC(C)(*)N(*)C*(C)C*(C)C1 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52423403P | 2003-11-21 | 2003-11-21 | |
| US60/524,234 | 2003-11-21 | ||
| PCT/US2004/038975 WO2005051946A2 (en) | 2003-11-21 | 2004-11-19 | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011121065A Division JP2011190271A (ja) | 2003-11-21 | 2011-05-30 | β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007514662A JP2007514662A (ja) | 2007-06-07 |
| JP2007514662A5 true JP2007514662A5 (https=) | 2007-12-06 |
| JP4851937B2 JP4851937B2 (ja) | 2012-01-11 |
Family
ID=34632881
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541552A Expired - Fee Related JP4851937B2 (ja) | 2003-11-21 | 2004-11-19 | β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物 |
| JP2011121065A Withdrawn JP2011190271A (ja) | 2003-11-21 | 2011-05-30 | β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011121065A Withdrawn JP2011190271A (ja) | 2003-11-21 | 2011-05-30 | β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7345060B2 (https=) |
| EP (1) | EP1685118B1 (https=) |
| JP (2) | JP4851937B2 (https=) |
| CN (1) | CN100569760C (https=) |
| AT (1) | ATE435855T1 (https=) |
| CA (1) | CA2543858C (https=) |
| DE (1) | DE602004021959D1 (https=) |
| ES (1) | ES2329586T3 (https=) |
| WO (1) | WO2005051946A2 (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693202B1 (en) * | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| TW200519108A (en) * | 2003-07-17 | 2005-06-16 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| PE20050711A1 (es) * | 2003-07-17 | 2005-09-10 | Glaxo Group Ltd | Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina |
| PE20050327A1 (es) * | 2003-07-17 | 2005-06-08 | Glaxo Group Ltd | Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de los receptores muscarinicos de la acetilcolina |
| AP2007004239A0 (en) * | 2003-10-14 | 2007-12-31 | Glaxo Group Ltd | Muscarinic acetycholine receptor antagonists |
| BRPI0415281A (pt) * | 2003-10-17 | 2006-12-19 | Glaxo Group Ltd | antagonistas de receptor de acetilcolina muscarìnico |
| PE20050489A1 (es) * | 2003-11-04 | 2005-09-02 | Glaxo Group Ltd | Antagonistas de receptores de acetilcolina muscarinicos |
| US7345060B2 (en) * | 2003-11-21 | 2008-03-18 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| US7262205B2 (en) | 2004-03-11 | 2007-08-28 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US20090253908A1 (en) * | 2004-03-11 | 2009-10-08 | Glaxo Group Limited | Novel m3 muscarinic acetylchoine receptor antagonists |
| JP2007528413A (ja) * | 2004-03-11 | 2007-10-11 | セラヴァンス， インコーポレーテッド | ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物 |
| TWI341836B (en) * | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| JP2007528412A (ja) * | 2004-03-11 | 2007-10-11 | セラヴァンス， インコーポレーテッド | ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物 |
| WO2005087735A1 (en) | 2004-03-11 | 2005-09-22 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| EP1723115A1 (en) | 2004-03-11 | 2006-11-22 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| TW200538095A (en) * | 2004-03-11 | 2005-12-01 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| PE20060259A1 (es) | 2004-04-27 | 2006-03-25 | Glaxo Group Ltd | Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico |
| JP2007537261A (ja) * | 2004-05-13 | 2007-12-20 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
| US7569586B2 (en) * | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| JP2008510014A (ja) * | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| US7659403B2 (en) | 2005-03-10 | 2010-02-09 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| TW200714587A (en) * | 2005-03-10 | 2007-04-16 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| WO2006099167A1 (en) * | 2005-03-10 | 2006-09-21 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| EP1856049A1 (en) * | 2005-03-10 | 2007-11-21 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| EP1856112A1 (en) * | 2005-03-10 | 2007-11-21 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| WO2006138218A1 (en) | 2005-06-13 | 2006-12-28 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US8429052B2 (en) * | 2005-07-19 | 2013-04-23 | Lincoln National Life Insurance Company | Method and system for providing employer-sponsored retirement plan |
| WO2007016650A2 (en) * | 2005-08-02 | 2007-02-08 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| WO2007016639A2 (en) * | 2005-08-02 | 2007-02-08 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| WO2007022351A2 (en) * | 2005-08-18 | 2007-02-22 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| TW200811105A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| TW200811104A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Crystalline forms of a dimethylphenyl compound |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| SG175023A1 (en) * | 2009-04-14 | 2011-11-28 | Glaxo Group Ltd | Process for the preparation of a biphenyl-2-ylcarbamic acid ester |
| MX337126B (es) | 2009-05-29 | 2016-02-12 | Pearl Therapeutics Inc | Administracion respiratoria de agentes activos. |
| GB0913342D0 (en) * | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| WO2011081937A1 (en) | 2009-12-15 | 2011-07-07 | Gilead Sciences, Inc. | Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy |
| SG186708A1 (en) * | 2010-07-13 | 2013-02-28 | Theravance Inc | Process for preparing a biphenyl-2-ylcarbamic acid |
| WO2012032546A2 (en) * | 2010-09-08 | 2012-03-15 | Cadila Healthcare Limited | Process for the preparation of salmeterol and its intermediates |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| CN105106200A (zh) * | 2011-05-17 | 2015-12-02 | 珍珠治疗公司 | 用于呼吸递送两种或多种活性剂的组合物、方法和系统 |
| HRP20151317T1 (hr) | 2011-06-10 | 2016-01-01 | Chiesi Farmaceutici S.P.A. | Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora |
| CN103547575B (zh) | 2011-06-10 | 2016-08-17 | 奇斯药制品公司 | 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物 |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| NZ708738A (en) | 2012-12-06 | 2019-02-22 | Chiesi Farm Spa | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| WO2014086927A1 (en) | 2012-12-06 | 2014-06-12 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| TWI703138B (zh) | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| CN107074816B (zh) * | 2015-03-27 | 2020-07-17 | 四川海思科制药有限公司 | 一种杂环衍生物及其制备方法和在医药上的用途 |
| AR104828A1 (es) | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO |
| WO2017093208A1 (en) | 2015-12-03 | 2017-06-08 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| CN107849035B (zh) * | 2015-12-29 | 2021-12-10 | 四川海思科制药有限公司 | 一种苯基杂环衍生物及其在医药上的用途 |
| CN107849019A (zh) * | 2016-01-22 | 2018-03-27 | 四川海思科制药有限公司 | 一种氮杂环酰胺衍生物及其制备方法和在医药上的用途 |
| WO2018011090A1 (en) | 2016-07-13 | 2018-01-18 | Chiesi Farmaceutici S.P.A. | Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| CA3047023C (en) | 2016-12-14 | 2022-05-31 | Beijing Showby Pharmaceutical Co., Ltd. | Class of bifunctional compounds with quaternary ammonium salt structure |
| CN106632257B (zh) * | 2016-12-15 | 2019-02-12 | 上海市奉贤区中心医院 | Gsk961081及其中间体的合成方法 |
| WO2019015639A1 (zh) * | 2017-07-21 | 2019-01-24 | 四川海思科制药有限公司 | 一种氮杂环酰胺衍生物组合物及其制备 |
| WO2019015640A1 (zh) * | 2017-07-21 | 2019-01-24 | 四川海思科制药有限公司 | 一种氮杂环酰胺衍生物的盐、其晶型及其制备方法和用途 |
| CN111423434A (zh) * | 2019-01-09 | 2020-07-17 | 四川海思科制药有限公司 | 一种碳酰胺衍生物及其制备方法 |
| CN115093365B (zh) * | 2022-07-25 | 2023-07-25 | 沈阳药科大学 | 一种雷芬那辛的合成方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4181802A (en) | 1978-05-11 | 1980-01-01 | Janssen Pharmaceutica N.V. | 1-(Heterocyclylalkyl)-1,3-dihydro-2-H-benzimidazole-2-ones |
| DK443489D0 (da) | 1989-09-08 | 1989-09-08 | Ferrosan As | Substituerede urinstofforbindelser, deres fremstilling og anvendelse |
| IE914003A1 (en) | 1990-11-20 | 1992-05-20 | Astra Pharma Prod | Biologically Active Amines |
| GB9211172D0 (en) | 1992-05-27 | 1992-07-08 | Fisons Plc | Compounds |
| GB9210632D0 (en) | 1992-05-19 | 1992-07-01 | Fisons Plc | Compounds |
| US5648370A (en) | 1990-11-20 | 1997-07-15 | Astra Pharmaceuticals Limited | 7-(2-aminoethyl) benzothiazolones |
| CZ236894A3 (en) | 1992-03-31 | 1995-09-13 | Glaxo Group Ltd | Substituted phenylcarbonates and phenylureas, their use for the preparation of pharmaceutical preparations, pharmaceuticals containing thereof and process for preparing such compounds |
| CA2123728A1 (en) | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
| WO1995006635A1 (en) | 1993-09-02 | 1995-03-09 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| WO1995021820A1 (en) | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
| TW356468B (en) | 1995-09-15 | 1999-04-21 | Astra Pharma Prod | Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same |
| ATE205490T1 (de) | 1995-10-13 | 2001-09-15 | Banyu Pharma Co Ltd | Substituierte heteroaromatische derivate |
| GB9526511D0 (en) | 1995-12-23 | 1996-02-28 | Astra Pharma Prod | Pharmaceutically active compounds |
| PE92198A1 (es) | 1996-08-01 | 1999-01-09 | Banyu Pharma Co Ltd | Derivados de 1,4-piperidina disustituida que contienen fluor |
| WO1999009018A1 (en) | 1997-08-14 | 1999-02-25 | Kirin Beer Kabushiki Kaisha | BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY |
| EP1047691A1 (en) | 1997-12-12 | 2000-11-02 | Smithkline Beecham Plc | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
| SG80041A1 (en) | 1998-06-08 | 2001-04-17 | Advanced Medicine Inc | Muscarinic receptor antagonists |
| US6693202B1 (en) | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| SE9900693D0 (sv) | 1999-02-26 | 1999-02-26 | Astra Pharma Prod | Novel process |
| DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| SE9902936D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902935D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902938D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902937D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| AU783095B2 (en) | 1999-12-07 | 2005-09-22 | Theravance Biopharma R&D Ip, Llc | Carbamate derivatives having muscarinic receptor antagonist activity |
| UA73543C2 (uk) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| US6506901B2 (en) * | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
| JP4445704B2 (ja) | 2000-12-22 | 2010-04-07 | アルミラル・ソシエダッド・アノニマ | キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用 |
| US20030018019A1 (en) | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| AR040779A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion |
| PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| US7094790B2 (en) * | 2003-05-07 | 2006-08-22 | Abbott Laboratories | Fused bicyclic-substituted amines as histamine-3 receptor ligands |
| US7345060B2 (en) * | 2003-11-21 | 2008-03-18 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
-
2004
- 2004-11-19 US US10/992,927 patent/US7345060B2/en not_active Expired - Fee Related
- 2004-11-19 ES ES04811663T patent/ES2329586T3/es not_active Expired - Lifetime
- 2004-11-19 JP JP2006541552A patent/JP4851937B2/ja not_active Expired - Fee Related
- 2004-11-19 EP EP04811663A patent/EP1685118B1/en not_active Expired - Lifetime
- 2004-11-19 DE DE602004021959T patent/DE602004021959D1/de not_active Expired - Lifetime
- 2004-11-19 AT AT04811663T patent/ATE435855T1/de not_active IP Right Cessation
- 2004-11-19 CN CNB2004800342018A patent/CN100569760C/zh not_active Expired - Fee Related
- 2004-11-19 WO PCT/US2004/038975 patent/WO2005051946A2/en not_active Ceased
- 2004-11-19 CA CA2543858A patent/CA2543858C/en not_active Expired - Fee Related
-
2007
- 2007-12-11 US US12/001,362 patent/US7842704B2/en not_active Expired - Fee Related
- 2007-12-11 US US12/001,363 patent/US7838535B2/en not_active Expired - Fee Related
-
2010
- 2010-10-13 US US12/903,365 patent/US8247564B2/en not_active Expired - Fee Related
-
2011
- 2011-05-30 JP JP2011121065A patent/JP2011190271A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007514662A5 (https=) | ||
| JP2007501862A5 (https=) | ||
| JP2008510015A5 (https=) | ||
| JP2006522134A5 (https=) | ||
| JP2008510014A5 (https=) | ||
| JP4851937B2 (ja) | β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物 | |
| RU2015101032A (ru) | ДИАМИДНЫЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ АНТАГОНИСТА МУСКАРИНОВОГО РЕЦЕПТОРА И АКТИВНОСТЬЮ АГОНИСТА β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| JPWO2003020313A1 (ja) | スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤 | |
| RU2008146383A (ru) | ДИАЛКИЛФЕНИЛЬНЫЕ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МУСКАРИНОВЫХ РЕЦЕПТОРОВ | |
| RU2009104764A (ru) | Производные пурина, как антангонисты a2a | |
| JP2018172387A5 (https=) | ||
| EP1613321A2 (en) | Muscarinic m1 receptor agonists for pain management | |
| JP4582456B2 (ja) | ８−アザプロスタグランジン誘導体およびその医薬用途 | |
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| US7566728B2 (en) | Remedy for sleep disturbance | |
| RU2314809C2 (ru) | Способ лечения депрессии соединениями-агонистами дельта-рецепторов | |
| RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
| US10137113B2 (en) | 5-HT4 receptor agonist as a prokinetic agent | |
| CN101663035B (zh) | 4-环丙基甲氧基-n-(3，5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途 | |
| JP2017516824A5 (https=) | ||
| WO2019197670A1 (en) | (s)-enantiomeric form of a heterocyclic compound having motivation improving and/or reference memory enhancing activity | |
| JP2008517907A5 (https=) | ||
| US20070004777A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
| JP2012006869A (ja) | ピリミジノン化合物およびその医薬用途 | |
| JPWO2020174283A5 (https=) |